References: 1. LaForce C, Brooks E, Herje N, Dorinsky P, Rickard K. Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinic. Ann Allergy Asthma Immunol. 2014;113(6):619-623. 2. Hanania NA, Alpan, O, Hamilos, DL et al. Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy. Ann Intern Med. 2011;154:573-582. 3. Dweik RA, Boggs PB, Erzurum SC, et al; on behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-615. 4. American Academy of Allergy, Asthma, and Immunology and American College of Allergy, Asthma, and Immunology. AAAAI/ACAAI joint statement of support of the ATS clinical practice guideline: interpretation of exhaled nitric oxide for clinical applications. https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/My%20Membership/FeNOJointStatement3-6-12.pdf. Accessed March 31, 2016. 5. British Thoracic Society. British guideline on the management of asthma: A national clinical guideline, 2016. Available at: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/. 6. Agency for Healthcare Research and Quality (ARHQ). The clinical utility of fractional exhaled nitric oxide (FeNO) in asthma management. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/cer-197-fractional-exhaled-nitricoxide_0.pdf. Accessed February 26, 2018. 7. NICE guideline [NG80]: Asthma: diagnosis, monitoring and chronic asthma management. Published November 2017: https://www.nice.org.uk/guidance/ng80. 8. Data on file. Circassia Pharmaceuticals.